For immediate release
Contact: Gary Sender
Chief Financial Officer
Tengion, Inc.
gary.sender@tengion.com
EAST NORRITON, PA, January 30, 2008 — Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-vessels, announced today that Steven Nichtberger, M.D., President and Chief Executive Officer, will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on Tuesday, February 5, 2008 at 9:20 a.m. EST. The conference will be held at the Grand Hyatt Hotel in New York City.
About Tengion
Tengion, a clinical stage biotechnology company, has pioneered the Autologous Organ Regeneration Platform™ that catalyzes the body's innate ability to regenerate. Tengion's neo-organs and neo-tissues in development, such as bladders and vessels, combine biocompatible materials and a patient's own (autologous) cells to regenerate diseased and failing organs and tissues. Tengion's product candidates have the potential to cure - rather than treat - organ and tissue failure, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.